SNP 162
Alternative Names: SNP-162Latest Information Update: 28 Aug 2023
At a glance
- Originator Snap Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Liver cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Liver-cancer in USA
- 28 Aug 2023 No recent reports of development identified for research development in Cancer in USA
- 26 Jul 2019 SNP 162 is available for licensing as of 26 Jul 2019. http://www.snap-bio.com/partnering (SnapBio pipeline July 2019)